[HTML][HTML] Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma
Journal of Clinical Oncology, 2018•ncbi.nlm.nih.gov
Purpose No standard treatment exists for patients with cholangiocarcinoma for whom first-
line gemcitabine-based therapy fails. Fibroblast growth factor receptor 2 (FGFR2)
fusions/translocations are present in 13% to 17% of intrahepatic cholangiocarcinomas.
BGJ398, an orally bioavailable, selective pan-FGFR kinase inhibitor, has shown preliminary
clinical activity against tumors with FGFR alterations. Methods
line gemcitabine-based therapy fails. Fibroblast growth factor receptor 2 (FGFR2)
fusions/translocations are present in 13% to 17% of intrahepatic cholangiocarcinomas.
BGJ398, an orally bioavailable, selective pan-FGFR kinase inhibitor, has shown preliminary
clinical activity against tumors with FGFR alterations. Methods
Abstract
Purpose
No standard treatment exists for patients with cholangiocarcinoma for whom first-line gemcitabine-based therapy fails. Fibroblast growth factor receptor 2 (FGFR2) fusions/translocations are present in 13% to 17% of intrahepatic cholangiocarcinomas. BGJ398, an orally bioavailable, selective pan-FGFR kinase inhibitor, has shown preliminary clinical activity against tumors with FGFR alterations.
Methods
ncbi.nlm.nih.gov
